Illustration by Allure; Source images: Getty ImagesSave StorySave this storySave StorySave this story

A spot appeared overnight on my left forearm. One morning there was nothing there; the next, there was a small, scaly, faintly-pink and slightly-raised patch.

I've always been vigilant about monitoring my skin for unusual spots since I have a family history of melanoma in addition to the fact that I’ve worked in the skin-care industry for the past two decades. I get annual skin checks, and I know the ABCDE skin cancer warning signs by heart… so I did what any person would do in 2026 and went down a ChatGPT and Google rabbit hole.

I managed to convince myself it was eczema—which usually presents itself in the form of patches of dry, itchy skin—based on internet photos and my general knowledge of skin conditions. But two days later, and after trying to slough off the scales with a gentle cleanser and towel, nothing changed. That’s when I started to wonder if it might be basal cell carcinoma—a very common skin cancer that’s usually treatable if caught early—and scheduled an appointment with my dermatologist right away.

“I have a weird spot. It came out of nowhere. I think it might be a basal cell… and my maternal aunt and maternal grandmother both died of melanoma,” I told the receptionist in a slightly panicked voice.

“We can get you in next week at our Santa Monica office.”

DONE. And I felt relieved given the usual wait time to see a dermatologist.

Well, turns out my ChatGPT diagnosis was wrong. It was neither eczema nor skin cancer.

The diagnosis, after two biopsies, two dermatologists, two pathologists and a referral to a cancer specialist, was cutaneous lymphoma—specifically mycosis fungoides, the most common form of cutaneous T-cell lymphoma (CTCL). It’s a rare blood cancer most common in men over 50. One that originates not in skin cells, but in immune cells that migrate to the skin and begin growing there.

As utterly shocked as I was to be diagnosed with a rare blood cancer at 42, I also knew that I was so lucky. My dermatologist caught something most people miss for years. And with any medical issue, especially with cancer, early diagnosis is key.

What Is Cutaneous Lymphoma?

To understand why cutaneous lymphoma is so frequently overlooked, it helps to understand what it actually is—and what it isn't. I put that question to Christiane Querfeld, MD, PhD, a professor of dermatology and dermatopathology and director of the cutaneous lymphoma program at City of Hope Cancer Center in Duarte, California—the specialist who would ultimately confirm my own diagnosis.

“Cutaneous lymphoma is a rare type of cancer that starts not in the skin cells themselves, but in immune cells—white blood cells called lymphocytes—that travel to the skin and begin to grow there,” Dr. Querfeld explains. “So while it can look like a simple rash, it's actually a cancer of the blood and immune system.”

That distinction matters enormously for diagnosis. Unlike melanoma or squamous cell carcinoma, which are caused by UV exposure, cutaneous lymphoma has no known environmental trigger. Researchers are investigating links to genetic factors and chronic immune inflammation, but there's no sun-damage story to trace, no clear cause to point to. It primarily affects adults over 50, with a peak incidence in the 60s and 70s, and is slightly more common in men—though it can and does occur across demographics (clearly).

Because the cancer cells initially settle within the skin rather than forming distinct tumors, the body responds with local inflammation. That inflammation triggers the same redness, scaling, and intense itching typically associated with eczema or psoriasis. “In its early stages, the cellular patterns can look so similar under a microscope that even a biopsy cannot always distinguish cutaneous lymphoma from a benign rash,” says Dr. Querfeld.

The result: the average patient waits three to ten years for an accurate diagnosis—time during which the disease can slowly progress from flat patches into thicker plaques, and in more advanced cases, spread beyond the skin entirely and into organs.

Why Dermatologists Often Miss Cutaneous Lymphoma

When I first saw Lubomira Scherschun, MD, a board-certified dermatologist at the Dermatology Institute of Southern California in Santa Monica, California, she biopsied a sample of my spot immediately. “When I saw the area, I knew I wanted to biopsy it because of the pink color and texture,” she told me. “It did not appear like typical eczema.”

The first biopsy came back suspicious but not definitive. Dr. Scherschun then referred me to Daniel Behroozan, MD, a double board-certified dermatologist and dermatologic surgeon at the Dermatology Institute of Southern California’s Beverly Hills branch. “Differentiating CTCL from eczema is sometimes impossible, and that's what makes the diagnosis difficult and sometimes delayed,” explains Dr. Behroozan.

He ordered a second biopsy—this time removing the entire lesion—for two reasons: to get rid of it, and to give pathology a larger tissue sample to examine. “Your initial biopsy was suspicious for CTCL, but not diagnostic,” he explains, “and since the eruption had not been resolved, we opted to just remove the whole thing.”

Even that biopsy wasn't guaranteed to give a clean answer. Early-stage cutaneous lymphoma is notoriously difficult to confirm on tissue alone. “Cancer cells at this stage are sparse and spread out; under a microscope, a single sample might look nearly normal,” explains Dr. Querfeld. It often takes multiple biopsies over months or years before a pattern becomes clear enough to confirm.

One study of over 400 patients reported a median of three years from initial CTCL symptoms to a confirmed diagnosis, which is both highly frustrating and medically consequential. Left undetected, the disease can slowly evolve from flat patches into thicker raised plaques, and in more advanced cases, spread beyond the skin into the lymph nodes or bloodstream, where it becomes significantly harder to treat.

Not every dermatologist would have moved as quickly as mine did—and given the statistics, that's understandable. “Because eczema and psoriasis are so common, and cutaneous lymphomas are so rare, it's not always at the top of our differential diagnosis,” Dr. Behroozan tells me, adding that his clinic typically diagnoses one to two cases of CTCL per year. In the United States, there are about 3,000 new cases of CTCL reported each year, according to the Cutaneous Lymphoma Foundation. In comparison, per the National Eczema Foundation, some 31.6 million Americans are living with some form of eczema.

The rash itself doesn't make things easier. Both conditions—CTCL and eczema—share a near-identical visual vocabulary: pink or red patches, dry or scaly texture, possible itching. The location can sometimes offer a clue; early cutaneous lymphoma patches often appear in “bathing suit” areas like the hips, buttocks, and breasts, regions typically protected from sun exposure. But not always, like in my case. “Sometimes the distribution can help differentiate it,” Dr. Querfeld says, “but not always, which is what makes it tricky.”

Cutaneous Lymphoma Warning Signs Worth Knowing

None of the specialists I spoke with want patients to panic every time they have a dry patch. But there are patterns worth paying attention to.

The most important thing is persistence. A rash that doesn't respond to standard treatments (steroid creams, moisturizers) after several weeks, or that keeps returning in the same location is worth escalating.

“Simply using stronger creams isn't enough,” Dr. Querfeld says. “You need a skin biopsy to get a real answer.”

Other red flags include patches that feel thin, slightly wrinkled, or have the texture of cigarette paper; lesions that partially improve and then worsen again but never truly clear; and itching that seems out of proportion to how mild the rash appears. A combination of these patterns—especially in someone who has been treating something as eczema for months without resolution—should prompt a conversation about biopsy.

Dr. Behroozan's threshold is straightforward: “If a rash persists for more than several days or weeks, it should be evaluated by a board-certified dermatologist.” And if you feel like something isn't being taken seriously, you can always ask directly for a biopsy. “A patient can always ask,” he says. “As physicians, we try to balance risk and benefit, but the patient's best interest is always the priority.”

My Cutaneous Lymphoma Diagnosis

After my results came back, Dr. Behroozan referred me to Dr. Querfeld at City of Hope, where her team confirmed the diagnosis: mycosis fungoides, Stage IA—the earliest possible stage. My cancer is limited to a single isolated patch, involving less than 10% of my skin surface. All blood work came back negative. Lymph nodes: normal.

“Because all tests for internal involvement were negative, your prognosis is excellent,” Dr. Querfeld told me. “Most patients at Stage IA have a normal life expectancy.”

Early-stage mycosis fungoides is treated with skin-directed therapies: medicated steroid creams, targeted light therapy, or localized radiation. It's generally considered a chronic, manageable condition rather than a curable one—lesions can recur—but for patients caught at Stage IA, the outlook is genuinely favorable. According to Dr. Querfeld, research is also advancing rapidly in the area of the tumor microenvironment, the ecosystem of healthy and immune cells that surround a tumor and can either help fight it or, in some cases, be co-opted by the cancer to help it hide and grow. Newer therapies are being designed to essentially flip that switch: reprogramming those surrounding immune cells to stop shielding the cancer and start attacking it instead.

It bears repeating, because I know how "lymphoma" lands: this is not the cancer most people imagine when they hear that word. It is not aggressive. It does not typically spread quickly. Dr. Behroozan was emphatic on this point when I told him I was working on this story: “Remind people that it is super rare. And it's not unusual if it's missed initially, even by an experienced dermatologist. Rashes evolve and can look very different from visit to visit.”

The more common skin cancers—basal cell carcinoma, squamous cell carcinoma, melanoma—remain far more prevalent and are exactly why routine annual skin checks matter. Get those checks. Know your skin. And if something appears that doesn't behave like a normal rash—if it persists, if it returns, if it simply refuses to resolve—push for answers.

That's the piece of advice every specialist I spoke with agreed on. You don’t need to panic if you have a weird rash or spot, but you absolutely should have it checked and also be your own best advocate.

That spot on my forearm appeared overnight. My diagnosis didn't. It took two biopsies, two dermatologists, two pathologists, and a specialist at one of the country's leading cancer centers over the course of several months. If there's anything I'd want another person to take from that, it's this: your health is worth fighting for. Don't let a “probably nothing” stop you from finding out for sure.